Abliva AB Interim Report January – March 2022
First quarter summary
Press releases
Abliva targets SEK 200 million raise to fund the KL1333 Phase 2/3 study to interim analysis
Abliva AB (Nasdaq Stockholm: ABLI) today announced that it intends to raise a financing round of SEK 200 million to provide the company with the capital necessary to run the Phase 2/3 study with KL133 ...
Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2022 held its Annual General Meeting (“AGM”). A summary of the resolutions follows.
Abliva to issue the Q1 Interim Report by May 31st
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that The Board of Directo ...
Abliva AB publishes 2021 Annual report
Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...
Notice of Annual General Meeting of Abliva AB (publ)
The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 1 p.m. on Friday, 20 May 2022 at Medicon Village, Scheeletorget ...
Abliva AB Year-End Report January – December 2021
"2021 was a defining year for Abliva, focused on portfolio delivering, de-risking our assets and building relationships as we prepared for success in 2022." - Ellen Donnelly, CEO
Resolution at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolution follows. The resolution was passed unanimously.